Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry

Atrial fibrillation (AF) is associated with substantially increased risk of cardiovascular events and overall mortality. The Atrial fibrillation Better Care (A—Avoid stroke, B—Better symptom management, C—Cardiovascular and comorbidity risk management) pathway provides a simple and comprehensive approach for integrated AF therapy. This study’s goals were to evaluate the ABC pathway compliance and determine the main gaps in AF management in the Middle East population, and to assess the impact of ABC pathway adherence on the all-cause mortality and composite outcome in AF patients. 2021 patients (mean age 57; 52% male) from the Gulf SAFE registry were studied. We evaluated: A—appropriate implementation of OACs according to CHA2DS2-VASc score; B—symptom control according to European Heart Rhythm Association (EHRA) symptom scale; C—proper cardiovascular comorbidities management. The primary endpoints were the composite cardiovascular outcome (ischemic stroke or systemic embolism, all-cause death and cardiovascular hospitalization) and all-cause mortality. One-hundred and sixty-eight (8.3%) patients were optimally managed according to adherence with the ABC pathway. Over the one-year follow up (FU), there were 578 composite outcome events and 224 deaths. Patients managed with integrated care had significantly lower rates for the composite outcome and mortality comparing to non-ABC group (20.8% vs. 29.3%, p = 0.02 and 7.3% vs. 13.1%, p = 0.033, respectively). On multivariable analysis, ABC compliance was independently associated with reduced risk of composite outcome (HR 0.53; 95% CI 0.36–0.8, p = 0.002) and death (HR 0.46; 95% CI 0.25–0.86, p = 0.015). Integrated ABC pathway adherent care resulted in the reduced composite outcome and all-cause mortality in AF patients from Middle East, highlighting the necessity of promoting comprehensive holistic and integrated care management of AF.

[1]  P. Friedman,et al.  Ischemic Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[2]  G. Lip,et al.  Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management , 2019, Journal of Human Hypertension.

[3]  G. Lip,et al.  A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention , 2019, Expert opinion on drug safety.

[4]  T. Chao,et al.  Should we judge stroke risk by static or dynamic risk scores? A focus on the dynamic nature of stroke and bleeding risks in patients with atrial fibrillation. , 2019, Journal of cardiovascular pharmacology.

[5]  G. Lip,et al.  Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study , 2019, Thrombosis and Haemostasis.

[6]  A. Farcomeni,et al.  ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. , 2019, The American journal of medicine.

[7]  F. Violi,et al.  Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. , 2019, Mayo Clinic proceedings.

[8]  G. Lip,et al.  Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. , 2018, American Journal of Medicine.

[9]  G. Boriani,et al.  Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. , 2018, European journal of internal medicine.

[10]  S. Connolly,et al.  Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). , 2017, The American journal of cardiology.

[11]  G. Lip The ABC pathway: an integrated approach to improve AF management , 2017, Nature Reviews Cardiology.

[12]  G. Lip,et al.  Stroke prevention in atrial fibrillation: Past, present and future , 2017, Thrombosis and Haemostasis.

[13]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  Sally Hopewell,et al.  Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis , 2016, British Medical Journal.

[15]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[16]  M. Rienstra,et al.  Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study). , 2016, American heart journal.

[17]  M. Houmsse,et al.  The current approach of atrial fibrillation management , 2016, Avicenna Journal of Medicine.

[18]  H. Crijns,et al.  Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. , 2012, European heart journal.

[19]  M. Zubaid,et al.  Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): Design and Baseline Characteristics of Patients With Atrial Fibrillation in the Arab Middle East , 2011, Circulation. Cardiovascular quality and outcomes.

[20]  S. Lévy,et al.  Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. , 2007, American heart journal.

[21]  S. Connolly,et al.  Title: Predictors of Mortality in Patients with Atrial Fibrillation (From the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events , 2017 .